Compare Stocks

Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company has a collaboration agreement with the University of Exeter for exploring the use of ketamine-assisted therapy to treat Severe AUD. Awakn Life Sciences Corp. is headquartered in Toronto, Canada.

Numinus Wellness, Inc. operates as a Canadian health care company empowering healing and wellness through the development and delivery of safe, evidence-based psychedelic-assisted therapies for mental illness, substance abuse and trauma. The Numinus model comprises psychedelic production, clinical research and clinical care, with a Health Canada-licenced research facility, seasoned medical team and growing network of clinics. The company's licence allows for a range of research activities and import, export and distribution of psychedelic substances including DMT, ketamine, LSD, MDMA, mescaline, psilocybin, psilocin. It operates through the following segments: Salvation Botanicals, Numinus Health and Salvation Bioscience. The Salvation Botanicals segment engages in psychedelic substance research, developing intellectual property while offering analytics services for revenue generation. Its laboratory provides services including cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics. The Numinus Health segment operates the wellness centre where professional therapists and health professionals use supportive therapies and

Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, solutions, and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services, and digital solutions and applications for managing treatment and therapy. Its Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms. It offers essential technical customer service, such as maintenance and repair; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as digital healthhcare consulting, products, and services. The company is headquartered in Forchheim, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.

SQI Diagnostics Inc., a precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide. The company also offers TOR-dx, a lung test, which enables the surgeon to assess the health of the donor's lung; and a COVID-19 at-home antibody test kit; the RALI-Dx, a COVID-19 severity triage lab test; and RALI-fast, a COVID-19 severity triage POC test. In addition, it offers microarray tests for protein and antibody testing workflow. The company was founded in 1999 and is headquartered in Toronto, Canada.